Gene-Disorder Association · Article
Gene
STK11 Serine/Threonine Kinase 11
×
First reported
2008
Supporting publications
3
Manually curated Approved treatment annotated
Association Review
In brief The association between STK11 (Serine/Threonine Kinase 11) and Melanoma is well established and manually curated, with its 2 contributing sources — 1 of them expert-curated — recording likely-pathogenic variants.
Sources
2
Clinical variants
4
Symptoms
2
Compounds
3
Trials
585 of 4,672 via STK11 compounds
Publications
3
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
ClinVar and variant evidence
Genetic basis 4 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access
06
Interventions
Therapeutics 3 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 4,672 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
3 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 9 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access